Castle Creek Pharmaceuticals, LLC
7
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
14.3%
1 terminated/withdrawn out of 7 trials
85.7%
-0.8% vs industry average
0%
0 trials in Phase 3/4
117%
7 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Role: lead
To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)
Role: lead
A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers
Role: lead
A 21 Day Irritation Study in Healthy Volunteers With Diacerein 1% Ointment
Role: lead
A 6-Week Study to Evaluate the Photoallergic Potential of Diacerein 1% Ointment in Healthy Volunteers
Role: lead
Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)
Role: lead
A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects
Role: lead
All 7 trials loaded